No Data
Isshintang: 2024 Annual Results Forecast
Opening more new stores but struggling to make a profit, Yixintang Pharmaceutical's net income is expected to drop by over 70% last year | Interpretations
① Yixintang Pharmaceutical expects a Net income decline of 72.7%–81.8% in 2024 compared to the same period last year; ② The company stated that the performance variation is mainly due to the expansion of the company's stores leading to increased Operation costs, as well as some new and relatively new stores being in the initial loss stage.
Yixintang Pharmaceutical (002727.SZ): Net income for the fiscal year 2024 is expected to decrease by 72.70%-81.80%.
Gelonghui, January 17丨Yixintang Pharmaceutical (002727.SZ) announced its 2024 performance forecast. The net income attributable to shareholders of the listed company is expected to be between 0.1 billion and 0.15 billion yuan, a decrease of 81.80%–72.70% compared to the same period last year; after excluding non-recurring gains and losses, the net income is expected to be between 0.25 billion and 0.35 billion yuan, a decrease of 65.87%–52.22% compared to the same period last year; earnings per share is expected to be between 0.1688 yuan/share and 0.2533 yuan/share. In terms of store expansion, as of December 31, 2024, the company has 11 directly operated chain stores.
Is Yixintang Pharmaceutical Group (SZSE:002727) A Risky Investment?
Yixintang Pharmaceutical (002727.SZ): Guizhou Yixintang invested 32.8 million yuan to acquire the relevant land use rights and the attached structures on it.
On December 27, Gelonghui reported that Yixintang Pharmaceutical (002727.SZ) announced that it would hold its sixth Board of Directors' seventh extraordinary meeting on December 26, 2024, to review and approve the proposal "to agree to the wholly-owned subsidiary Guizhou Hongxiang Yixintang Pharmaceutical Chain Co., Ltd. to externally invest to obtain land use rights and its attached properties." The proposal agrees to the wholly-owned subsidiary Guizhou Hongxiang Yixintang Pharmaceutical Chain Co., Ltd. (referred to as "Guizhou Yixintang") to invest with its own funds of 32.8 million RMB to acquire land located in the Longming District of Shuanglong New Area, Guiyang City from Guizhou Fanghong Industrial Co., Ltd. (referred to as "Guizhou Fanghong").
Investors Continue Waiting On Sidelines For Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)
4.8% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Yixintang Pharmaceutical Group (SZSE:002727) Shareholders Over That Period
